Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

9
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
9
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

13
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
13
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

16
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
16
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Autoimmune Disorders01:29

Autoimmune Disorders

2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Status of retained deciduous second molars in subjects with agenesis of second premolars in relation to age.

European journal of paediatric dentistry·2023
Same author

Computed tomography with positron emission tomography is more useful in local than systemic infectious process related to cardiac implanted electrotherapy device: a prospective controlled multicenter diagnostic intervention PET-Guidance Trial.

The international journal of cardiovascular imaging·2022
Same author

Diffusion tensor imaging findings in the multiple sclerosis patients and their relationships to various aspects of disability.

Journal of the neurological sciences·2018
Same author

Effect of Selective Antibiotic Pressure on the MLS-B Phenotype in Methicillin-Resistant Staphylococcus aureus Strains Originating From Patients From Transplantation Wards: 24 Years of Observations.

Transplantation proceedings·2018
Same author

Characteristics of the expression of KAI1/CD82 and PDGFRβ and their impact on glioma progression.

Folia neuropathologica·2016
Same author

Reversible cerebral vasoconstriction syndrome presenting with severe headache and seizures.

Neurology India·2016

Related Experiment Video

Updated: Apr 24, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

ALCAM and CD6--multiple sclerosis risk factors.

M Wagner1, M Bilinska2, A Pokryszko-Dragan2

  • 1Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland.

Journal of Neuroimmunology
|September 14, 2014
PubMed
Summary

The ALCAM gene is linked to multiple sclerosis (MS) risk and progression. CD6 gene variations and lower mRNA expression are also associated with MS, suggesting a role in disease pathogenesis.

Keywords:
Gene–gene interactionMultiple sclerosisPolymorphismmRNA expression

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K

Related Experiment Videos

Last Updated: Apr 24, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K

Area of Science:

  • Neuroimmunology
  • Genetics

Background:

  • Leukocyte transmigration across the blood-brain barrier is crucial in multiple sclerosis (MS) pathogenesis.
  • Cell adhesion molecules like Activated Leukocyte Cell Adhesion Molecule (ALCAM) and its receptor CD6 are implicated in this process.

Purpose of the Study:

  • To investigate the association of ALCAM and CD6 gene polymorphisms and CD6 mRNA expression with multiple sclerosis (MS).
  • To confirm previous findings on the ALCAM gene's role in MS risk, development, and progression.

Main Methods:

  • Genotyping for ALCAM and CD6 gene polymorphisms, including rs12360861.
  • Quantitative analysis of CD6 mRNA expression levels in MS patients and healthy controls.

Main Results:

  • The ALCAM gene association with MS risk, development, and progression was confirmed.
  • Specific ALCAM gene polymorphisms (rs12360861) showed a significantly lower risk for individuals with the AA genotype compared to GG (OR=0.34).
  • Lower CD6 mRNA expression was observed in MS patients compared to healthy individuals (p=0.002).

Conclusions:

  • Both ALCAM and CD6 play significant roles in multiple sclerosis (MS) pathogenesis.
  • CD6 gene polymorphisms and reduced mRNA expression are associated with MS, highlighting its importance beyond ALCAM binding.